Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro
about
In vitro and in vivo activities of syn2836, syn2869, syn2903, and syn2921: new series of triazole antifungal agentsMDR1-mediated drug resistance in Candida dubliniensisSynergy of nitric oxide and azoles against Candida species in vitro.Purpurin triggers caspase-independent apoptosis in Candida dubliniensis biofilmsRetrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals.Biofilm formation by Candida dubliniensis.The ins and outs of DNA fingerprinting the infectious fungiCandida dubliniensis: characteristics and identification.Rapid identification of Candida albicans and other human pathogenic yeasts by using short oligonucleotides in a PCRSimple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicansPrevalence of Candida dubliniensis isolates in a yeast stock collectionDetection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates.Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization of antigens on C. dubliniensis blastospores and Candida albicans germ tubes.Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensisComparison between Candida albicans agglutinin-like sequence gene expression patterns in human clinical specimens and models of vaginal candidiasis.Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.Molecular analysis of fungal populations in patients with oral candidiasis using internal transcribed spacer region.Longitudinal genotyping of Candida dubliniensis isolates reveals strain maintenance, microevolution, and the emergence of itraconazole resistance.Identification of Candida dubliniensis in a prospective study of patients in the United States.Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea.In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.Rapid identification of Candida dubliniensis with commercial yeast identification systems.Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in IsraelGrowth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions.Intraspecies diversity of Cryptococcus laurentii as revealed by sequences of internal transcribed spacer regions and 28S rRNA gene and taxonomic position of C. laurentii clinical isolates.Evaluation of phenotypic markers for selection and identification of Candida dubliniensis.Rapid identification of Candida dubliniensis using a species-specific molecular beacon.Serological differentiation of experimentally induced Candida dubliniensis and Candida albicans infectionsRecovery of Candida dubliniensis and other yeasts from human immunodeficiency virus-associated periodontal lesionsEffects of azole antifungal drugs on the transition from yeast cells to hyphae in susceptible and resistant isolates of the pathogenic yeast Candida albicans.Novel 5-flucytosine-resistant clade of Candida dubliniensis from Saudi Arabia and Egypt identified by Cd25 fingerprintingMolecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasisReplacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.Development and evaluation of a rapid latex agglutination test using a monoclonal antibody to identify Candida dubliniensis colonies.Multicenter study evaluating the Vitek MS system for identification of medically important yeasts.Susceptibility of Candida dubliniensis to salivary histatin 3.Prevalence of Candida species, including Candida dubliniensis, in Singapore.Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo.Candida dubliniensis at a university hospital in Saudi Arabia.Candida dubliniensis infections in a pediatric population: retrospective identification from clinical laboratory isolates of Candida albicans
P2860
Q28345946-6B51FF78-0473-43B6-95C4-D7024CD34564Q28364120-20C9FC57-8894-46C9-BDD1-98A0BC240768Q28368892-CFE99E67-A81F-44FE-9D6B-D74093FC3E95Q28537918-025C6861-F185-47E5-8607-878B5E365F20Q30596962-658A0846-34CB-4EF7-94F4-270A51C51F21Q30705127-BEE686EE-45B9-4430-B9F4-8C45D4EC6D4EQ33555593-6D8BC6EC-C718-4277-A0CA-C0885C47A777Q33655501-21FA48D0-1EE1-4DAC-9957-E6283466DC1FQ33669841-A9272978-EFCB-4835-8581-A9E00315D505Q33674167-4E7229AC-C635-4C2E-B56E-F104F6F950FBQ33678015-9049CF04-5FE6-45E4-ACFE-3E89E15199FAQ33679210-D9C3F4EF-48E4-4B25-87A4-D2A84355691DQ33681054-31C08E2E-A9FB-4BA1-B64F-A243394EE1DCQ33694469-2C06D8EB-E3EB-4ED1-8AFA-12B0770682E4Q33716106-03140CEA-5828-4D9F-BAA5-4464A87D5B63Q33721804-BA225F0D-E2ED-4677-A1BC-E6C49FB7CB62Q33825810-2FBBCBF2-2465-4E1B-9C90-8294DEB7ECD6Q33827085-F52D2DAA-8DD3-422F-92F4-F6C10F8E0F97Q33958617-96A46CD4-C4B6-4960-92D6-4CF9E1E1C92AQ33958755-380B3F5B-AC97-49A2-8672-0AA206E1C9CEQ33959506-9CB10C62-EF26-4D1B-8E77-B111D6135E6AQ33963510-38D1A678-4323-4D58-9E50-09AFE7C7D848Q33964932-B9FA4826-A208-487F-B908-3FACB3FA98E4Q33965665-53BE4E9E-7DA2-4E9E-B9E0-F44FC1D5C270Q33966402-074CBEF2-4CCC-4489-89CB-CA8F1EEBB1F3Q33966538-2D4D8F57-CC09-4AE6-A6F8-4BA87EAD5880Q33968704-9D6AD0A3-4758-43D0-AC49-A2AAF15D48A0Q33973230-8E009602-DE7F-4A9C-9F37-28E57D55C76BQ33974357-E16F2048-7E90-4513-A726-4ABFEEB5F7FAQ33976591-3C1F1FD8-0748-4B9E-B3C3-08443D0C4267Q34041713-8922EADE-93E8-40B9-B746-0E3B34189234Q34108536-EAFCA18E-504C-4CDF-B078-DFB5653DAD88Q34195821-DB79069F-AE4C-4041-BCB5-1B3517CD57CAQ34315485-F0FA2CCE-9980-486E-98FF-2A5DD7A14B9BQ34711725-7C0FF97B-912E-47DF-9304-444931BB7077Q34722920-57F29CBE-DD06-4A97-A9DE-30A6ABD9FF0CQ34747519-03701FF2-58E7-447B-B94F-9DBB7320EB19Q34947163-D1A55B26-CA0E-49C3-8347-08A1C28BB240Q34992130-90210D30-BBDD-4E9D-9B0F-652E35D0C5D8Q35156996-5525A77B-326F-44BD-80EE-1F9FFCD97639
P2860
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro
description
1997 nî lūn-bûn
@nan
1997 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մարտին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Antifungal drug susceptibiliti ...... resistant derivatives in vitro
@ast
Antifungal drug susceptibiliti ...... resistant derivatives in vitro
@en
Antifungal drug susceptibiliti ...... resistant derivatives in vitro
@nl
type
label
Antifungal drug susceptibiliti ...... resistant derivatives in vitro
@ast
Antifungal drug susceptibiliti ...... resistant derivatives in vitro
@en
Antifungal drug susceptibiliti ...... resistant derivatives in vitro
@nl
prefLabel
Antifungal drug susceptibiliti ...... resistant derivatives in vitro
@ast
Antifungal drug susceptibiliti ...... resistant derivatives in vitro
@en
Antifungal drug susceptibiliti ...... resistant derivatives in vitro
@nl
P2093
P2860
P356
P1476
Antifungal drug susceptibiliti ...... resistant derivatives in vitro
@en
P2093
Coleman DC
Harrington BJ
McCreary CE
Shanley DB
Sullivan DJ
P2860
P304
P356
10.1128/AAC.41.3.617
P407
P577
1997-03-01T00:00:00Z